Manitou Investment Management Ltd. Has $46.68 Million Stock Position in IDEXX Laboratories, Inc. $IDXX

by · The Markets Daily

Manitou Investment Management Ltd. trimmed its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 27.4% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 68,992 shares of the company’s stock after selling 26,085 shares during the period. IDEXX Laboratories comprises 8.2% of Manitou Investment Management Ltd.’s investment portfolio, making the stock its 5th biggest position. Manitou Investment Management Ltd. owned approximately 0.09% of IDEXX Laboratories worth $46,675,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Virtus Advisers LLC bought a new stake in IDEXX Laboratories in the 3rd quarter worth about $26,000. Park Place Capital Corp bought a new stake in IDEXX Laboratories in the 4th quarter worth about $29,000. WealthCollab LLC bought a new stake in IDEXX Laboratories in the 2nd quarter worth about $30,000. Caitong International Asset Management Co. Ltd bought a new stake in IDEXX Laboratories in the 3rd quarter worth about $36,000. Finally, Mowery & Schoenfeld Wealth Management LLC grew its position in IDEXX Laboratories by 58.8% in the 4th quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company’s stock worth $37,000 after purchasing an additional 20 shares in the last quarter. 87.84% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on IDXX shares. Stifel Nicolaus reduced their price objective on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research report on Tuesday, March 31st. Wall Street Zen cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Piper Sandler dropped their target price on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a research note on Monday, February 9th. UBS Group dropped their target price on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 28th. Finally, Weiss Ratings cut shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 11th. Seven analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and a consensus price target of $751.00.

Check Out Our Latest Stock Analysis on IDEXX Laboratories

IDEXX Laboratories Price Performance

Shares of NASDAQ:IDXX opened at $560.73 on Thursday. The company has a 50 day moving average of $563.43 and a 200 day moving average of $633.51. The stock has a market cap of $44.23 billion, a P/E ratio of 41.29, a P/E/G ratio of 3.20 and a beta of 1.55. IDEXX Laboratories, Inc. has a 12 month low of $506.91 and a 12 month high of $769.98. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19.

IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, beating the consensus estimate of $3.41 by $0.06. The company had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. IDEXX Laboratories’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, sell-side analysts forecast that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

IDEXX Laboratories Company Profile

(Free Report)

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

Read More